130 166

Cited 0 times in

SGLT2 억제제의 심혈관 질환에 대한 임상연구 결과와 심장 보호효과의 가능한 기전

Other Titles
 Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism 
Authors
 조용인  ;  강은석 
Citation
 Journal of Lipid and Atherosclerosis, Vol.7(1) : 21-31, 2018 
Journal Title
 Journal of Lipid and Atherosclerosis 
ISSN
 2287-2892 
Issue Date
2018
Keywords
Sodium-glucose co transporter 2 inhibitors ; Cardiovascular outcome ; Cardioprotective mechanism
Abstract
Patients with type 2 diabetes (T2D) have a significantly higher risk of developing cardiovascular diseases such as myocardial infarction, heart failure, and stroke. Current anti-diabetic drugs are highly effective for managing hyperglycemia. However, most T2D patients are still at high risk for cardiovascular disease. Over the past decade, many studies have assessed the efficacy of anti-diabetic drugs in regards to cardiovascular disease outcomes in T2D patients. However, despite the effective glycemic control of these drugs, they failed to show significant benefits that impact the morbidity and mortality of cardiovascular disease (CVD). In recent years, anti-diabetic drugs, developed with other mechanisms, have shown significant results for improving the risk of CVD. In addition, sodium glucose cotransporter 2 inhibitors have shown promising results that impact CVD outcomes in several trials. This article will review the cardiovascular outcomes and possible cardioprotective mechanisms of sodium glucose cotransporter 2 inhibitors.
Files in This Item:
T201801972.pdf Download
DOI
10.12997/jla.2018.7.1.21
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Cho, Yong In(조용인) ORCID logo https://orcid.org/0000-0002-4645-816X
Export
RIS (EndNote)
XLS (Excel)
XML
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/162609
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse